SCHEMBL3751699

SCHEMBL3751699

Cc1cc(C(O)CN)n(C)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.37
POLB P06746 2/20 0.37
APAF1 O14727 1/20 0.37
BLM P54132 5/20 0.35
KDM4E B2RXH2 5/20 0.35
TDP1 Q9NUW8 4/20 0.35
TAAR1 Q96RJ0 3/20 0.35
APEX1 P27695 3/20 0.35
MAPT P10636 3/20 0.35
RECQL P46063 3/20 0.35
HPGD P15428 2/20 0.35
MAPK1 P28482 2/20 0.35
MEN1 O00255 1/20 0.35
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
ADRA2A P08913 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADRB3 P13945 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA2B P18089 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23240257 0.76 SMN1; SMN2 (0.39) LMNAPOLBAPAF1KDM4ERECQL
SCHEMBL3743611 0.75 ALDH1A1 (0.42) LMNAPOLBAPAF1KDM4EMAPT
SCHEMBL678753 0.71 SMN1; SMN2 (0.37) LMNAPOLBAPAF1KDM4EMAPK1
SCHEMBL19102161 0.71 GLS (0.34) LMNAPOLBAPAF1KDM4EHPGD
SCHEMBL24248353 0.71 PDE2A (0.36) LMNAPOLBAPAF1KDM4EHPGD
SCHEMBL334876 0.70 LMNA (0.34) LMNAPOLBAPAF1KDM4EHPGD
SCHEMBL15686686 0.70 MEN1 (0.42) LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL4360395 0.69 SMN1; SMN2 (0.44) LMNAPOLBAPAF1KDM4EMAPK1
SCHEMBL23686272 0.69 AAK1 (0.33) LMNAPOLBAPAF1TAAR1SMN1; SMN2
SCHEMBL10429623 0.68 LMNA (0.45) LMNAPOLBAPAF1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132015-A1 NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
WO-2010132015-A1 NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
US-20100292210-A1 Novel Compounds for A-Beta-Related Pathologies ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292210-A1 Novel Compounds for A-Beta-Related Pathologies ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292210-A1 Novel Compounds for A-Beta-Related Pathologies ASTRAZENECA AB (SE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292210-A1 Novel Compounds for A-Beta-Related Pathologies BACE1, APP, BACE2 LMNA 446/4885POLB 1602/4885APAF1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.